published meta-analysis   sensitivity analysis   studies

methylprednisolone in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsEdalatifard, 2020 0.29 [0.15; 0.56] Steroids-SARI, 2020 0.91 [0.29; 2.86] 0.47[0.16; 1.39]Edalatifard, 2020, Steroids-SARI, 2020265%108seriousnot evaluable deaths (time to event analysis only)detailed resultsEdalatifard, 2020 0.29 [0.15; 0.56] 0.29[0.15; 0.56]Edalatifard, 202010%62NAnot evaluable clinical improvementdetailed resultsEdalatifard, 2020 12.00 [2.39; 60.20] 12.00[2.39; 60.20]Edalatifard, 202010%62NAnot evaluable serious adverse eventsdetailed resultsEdalatifard, 2020 0.81 [0.11; 6.17] 0.81[0.11; 6.17]Edalatifard, 202010%62NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-03-28 14:31 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 733 - roots T: 290